SoCal Investors Await Clovis Oncology IPO

Two Southern California venture firms are among the investors who are awaiting an expected IPO of Clovis Oncology, a developer of cancer drugs, this week. Clovis Oncology, based in Colorado, is expected to price its IPO this week, according to the NASDAQ's expected IPO calendar. Clovis has applied to trade on the NASDAQ Global Market as CLVS. According to the latest S-1 filing for Clovis, two of its major investors are based in Southern California, including San Diego-based Domain Associates, which owns 18.5 percent of the firm, and Newport Beach-based Versant Ventures, which owns 7.8 percent of the company. Other investors in the company include New Enterprise Associates, Aberdare Ventures, Abingworth Bioventures, and Pfizer. Clovis is seeking to raise up to $160M in the offering.